Spruce Biosciences, Inc.
SPRB Nasdaq
SEC CIK 1683553
Follow Spruce Biosciences
Weekly email: filings, results
Net income
−$24M
−192.3% vs same quarter last year
EPS, diluted
−$8.51
+41.6% vs same quarter last year
Operating cash flow
−$13.8M
−158.8% vs same quarter last year
Operating income
−$24M
−191.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$39M |
| FY24 | $4.9M | −$53M |
| FY23 | $10.1M | −$47.9M |
| FY22 | $0 | −$46.2M |
| FY21 | - | −$42.3M |
| FY20 | - | −$29.5M |
| FY19 | - | −$13.1M |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | −$56M |
| FY23 | −$33.3M |
| FY22 | −$41.7M |
| FY21 | −$36M |
| FY20 | −$27.6M |
| FY19 | −$12.6M |
| FY18 | - |